Background: Dyslipidemia, frequently occurring in type 2 diabetic patients, might play a critical role in accelerated macrovascular atherosclerotic changes lead to lethal coronary artery disease thus, timely intervention by lipid lowering agents may reduce complications. Aim is to establish the role of HbA1c as dual biomarker for long term glycemic control and associated dyslipidemia. Total of 481  samples were taken from type 2 diabetic patients and analyzed for fasting blood sugar (FBG), Hba1c and Lipid profile(cholesterol, triglycerides, HDL, LDL and VLDL). Patients were categorized based on glycemic control into three groups; HbA1c< 6% as good, HbA1c>6% – <9% as poor and HbA1c>9% as worst glycemic control.

Results: HbA1c was directly correlated with cholesterol, FBS, TG, LDL and VLDL, however inversely with HDL

Conclusion: Study established role of Hba1c as dual biomarker for long term glycemic control and dyslipidemia in type 2 diabetic patients